engleski

Patient-reported outcomes of PROBITECT-A emollient plus treatment in subjects with mild atopic dermatitis during a 4-week follow-up

PROBITECT-A is a new emollient plus lotion consisting of a cosmetic base (water-in-oil inverse emulsion with a high proportion of lipids) with three active ingredients based on microbiota (ectoin and a combination of inactivated Lactobacillus and Bifidobacterium bacterial strains preparations) designed for alleviating symptoms of atopic dermatitis (AD). One of the goals of the clinical study was to assess the quality of life and the intensity of pruritis during a 4 week PROBITECT-A treatment in adult AD patients. The study was designed as a comparison of two therapies, PROBITECT-A and control treatment (formulation without active ingredients), on adult patients with diagnosed mild atopic dermatitis. Treatments were applied twice daily on two sides of the body (left/right on the same patient) during 4 weeks. To assess the patient-reported outcomes, two questionnaires Dermatological Life Quality Index (DLQI) and Numeric Rating Scale (NRS) for average and worst pruritis (itching), were completed by enrolled subjects at day 0 (prior to applying the emollient) and then at weeks 2 and 4. Additionally, the patients reported the regularity, frequency and type of emollient use. From 84 recruited patients, 32 completed the study according to protocol. The majority of patients used the emollients regularly as prescribed (2xday) and did not use any other product. The results demonstrated that there was a significant reduction in the worst and average pruritis intensity as well as the improvement of DLQI at both week 2 and week 4 compared to day 0. The use of tested emollients significantly reduces the intensity of pruritis and improves the quality of life of patients with mild AD.

emollient plus, atopic dermatitis, clinical study

nije evidentirano